AI-generated analysis. Always verify with the original filing.
Atossa Therapeutics, Inc. filed an 8-K on February 20, 2026, reporting entry into an At the Market Offering Agreement and termination of a prior agreement with Jefferies LLC. The filing includes exhibits detailing these agreements.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry Into a Material Definitive Agreement. On February 20, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into the At the Market Offering Agreement, d
Termination of a Material Definitive Agreement. On February 19, 2026, the Company delivered written notice to Jefferies LLC indicating that it is terminating th
Financial Statements and Exhibits. (d) Exhibits 1.1 At the Market Offering Agreement, dated February 20, 2026, by and between Atossa Therapeutics, Inc. and Rodm
Material Agreement